SUBSCRIBE
SUBSCRIBE
News   Drug Development

AstraZeneca PLC Shares Leap After Its Drug Beats Plavix in Test

May 11, 2009 | 
1 min read

Bookmark and Share

Reuters -- AstraZeneca Plc’s experimental heart drug Brilinta has beaten Sanofi-Aventis SA and Bristol-Myers Squibb Co’s blockbuster Plavix in a pivotal clinical trial, lifting its shares sharply.

Clinical research Phase III Postmarket research
AstraZeneca Pharmaceuticals LP
MORE ON THIS TOPIC
Pictured: Boehringer Ingelheim sign on a building/
Schizophrenia
Boehringer Suffers Phase III Schizophrenia Fail, Legal Parry by HHS
January 17, 2025
 · 
2 min read
 · 
Tristan Manalac
Businessman jump careful on cracked or broken graph. Job opportunity and career. concept of under pressure. risk, financial, and tax
Pipeline
New Safety Signals Force Keros to Fully Terminate Mid-Stage PAH Study
January 15, 2025
 · 
2 min read
 · 
Tristan Manalac
Business
Dispatches From JPM, Biogen’s Sage Buyout Offer, Pfizer’s Obesity Play, More
January 15, 2025
 · 
1 min read
 · 
Heather McKenzie
Pictured: A sign on a J.P. Morgan building in Hong Kong/iStock, danielvfung
Pipeline
JPM25 Day One: Pfizer, BioNTech, Moderna and More Present Pipeline Updates
January 14, 2025
 · 
3 min read
 · 
Dan Samorodnitsky